Oct 2026· Frontiers in Medicine· Vol 13· 0 citations· 44 references
Medicine
TL;DR
Computed tomography biomarkers after neoadjuvant immunotherapy are examined, focusing on conventional and dual-energy CT, radiomics, delta-radiomics, and deep-learning models.
Abstract
Neoadjuvant immune checkpoint blockade, usually combined with platinum-based chemotherapy, has improved pathologic response and event-free survival in patients with resectable non-small cell lung cancer (NSCLC). Preoperative assessment remains difficult, however, because radiographic change does not directly represent the amount of residual viable tumor. Immune-cell infiltration, edema, necrosis, granulomatous nodal reactions, and reparative fibrosis may preserve tumor size despite major or complete pathologic response, whereas small viable tumor nests may remain within an apparently fibrotic bed. This Mini Review examines computed tomography (CT) biomarkers after neoadjuvant immunotherapy, focusing on conventional and dual-energy CT, radiomics, delta-radiomics, and deep-learning models. Size-based response criteria are reproducible but insufficient for tissue characterization. Selected, predominantly retrospective studies suggest that temporal models can add information, but transportability and clinical utility remain uncertain. We distinguish four intended uses: pathologic-response prediction, nodal restaging, technical resectability and operative-complexity assessment, and prognosis. Conventional CT informs anatomy and complication assessment; quantitative response models remain investigational. Suspicious new or enlarging nodes warrant tissue confirmation when the result would alter curative surgery. A structured reporting checklist links imaging uncertainty to multidisciplinary action. Imaging biomarkers should complement clinical, pathologic, and molecular data and should not currently be used to omit surgery.
BACKGROUND
Surgical timing after neoadjuvant therapy for borderline resectable pancreatic cancer remains difficult because post-treatment imaging may not reliably distinguish residual tumor from fibrosis, whereas tumor biology and patient fitness strongly influence surgical benefit.
METHODS
We performed a critical na...
Wai-San Ho, Wen-Chao Xu, Jian-Lu Zhang et al.· Journal of Gastrointestinal...· 0 citations
This study establishes a noninvasive spatiotemporal heterogeneity biomarker based on 18F-FDG PET-CT that reliably predicts treatment response and prognostic outcomes in unresectable LA-NSCLC and offers valuable insights for personalized clinical decision making and supports precision oncology.
Yuan-Yuan Ji, Jia-Qi Wang, Mei-Xia Zhou et al.· JCO Precision Oncology· 0 citations
Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet treatment benefit remains heterogeneous and resistance is common. Genomic alterations, tumor microenvironment (TME) remodeling, and metabolic reprogramming across spatial and temporal scales that are incompletely cap...
Ran Zhang, Xiao-Qing Ji, Shu-Ran Yang et al.· Frontiers in Immunology· 0 citations
It is suggested that uPAR PET captures invasion-related tumor biology that is not fully reflected by glucose metabolism imaging that is not fully reflected by glucose metabolism imaging in non-small cell lung cancer.
P. Soldath, M. Clausen, Annika Loft et al.· Journal of Nuclear Medicine· 0 citations
These findings should be interpreted cautiously because area under the receiver operating characteristic curve (AUC) alone does not establish clinical utility, and Prospective, multicentre validation studies reporting sensitivity, specificity, predictive values, likelihood ratios, calibration, and decision curve analys...
Yun-Lin Luo, You-Ping Ding, Wei Liu et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.